Purdue Pharma, Sackler family agree on historic settlement over OxyContin


This recording was made using enhanced software.

Full story

Purdue Pharma and the Sackler family have agreed to pay more than $7 billion to settle claims over their role in fueling the U.S. opioid epidemic. This settlement is the latest chapter in a legal battle over the company’s widely prescribed painkiller, OxyContin. Experts describe it as a gateway drug to harder substances like heroin.

$7.4 billion settlement amid opioid crisis

The deal, which involves 15 states, comes after years of litigation and a 2024 U.S. Supreme Court ruling that blocked a previous agreement. The deal had proposed granting the Sackler family immunity from future lawsuits, a provision five of the justices found unacceptable.

QR code for SAN app download

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.

Point phone camera here

Since OxyContin’s launch in 1999, Purdue Pharma has marketed the drug as a safe pain management solution despite being aware of its highly addictive properties. This lack of transparency is cited as a key factor behind increased opioid overdose deaths in the U.S. over the past two decades.

Settlement details and impact

The Sackler family plans to contribute most of the settlement. That includes an initial payment of $1.5 billion and also additional payments over the next three years. Purdue Pharma, now bankrupt, will also contribute $900 million. The funds will be used to support opioid addiction treatment and prevention programs nationwide, addressing the ongoing crisis claiming thousands of lives each year.

“Families throughout New York and across the nation are suffering from the immense pain and loss wrought by the opioid crisis,” said New York Attorney General Letitia James, who played a key role in securing the settlement. James worked alongside attorneys general from California, Colorado, Connecticut and 11 other states to bring the lawsuit to a close.

Purdue’s future and the Sacklers’ accountability

As part of the settlement, the Sacklers will lose ownership of Purdue Pharma as it enters bankruptcy proceedings. They will also be banned from selling opioids in the U.S.

While the settlement represents a significant financial commitment, the attorneys representing each state argue it can never truly compensate for the lives lost or the lasting impact of the opioid crisis.

Purdue expressed satisfaction with the new agreement. The company wrote in a statement, “We are extremely pleased that a new agreement has been reached that will deliver billions of dollars to compensate victims, abate the opioid crisis, and deliver treatment and overdose rescue medicines that will save lives.”

The settlement is still subject to court approval. Once finalized, the funds will be distributed to victims and communities affected by the opioid crisis. The details of the distribution process are still being worked out.

Tags: , , , , ,

Straight Arrow
Fear No Fact.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Straight Arrow
Fear No Fact.

Don't just take our word for it.


Certified balanced reporting

According to media bias experts at AllSides

AllSides Certified Balanced May 2025

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Media landscape

Click on bars to see headlines

187 total sources

Key points from the Left

No summary available because of a lack of coverage.

Report an issue with this summary

Key points from the Center

No summary available because of a lack of coverage.

Report an issue with this summary

Key points from the Right

No summary available because of a lack of coverage.

Report an issue with this summary

Other (sources without bias rating):

Powered by Ground News™